HPV-related OPC: how do 8th-edition AJCC guidelines affect staging of TORS patients?

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In a retrospective study, 94% of patients with human papillomavirus (HPV)-positive oropharyngeal cancer (OPC) treated with transoral robotic surgery (TORS) are stage I under the 8th edition American Joint Committee on Cancer (AJCC) staging system vs just 5% under 7th edition guidelines.

Why this matters

  • HPV-positive patients generally have better prognosis than HPV-negative patients; the 8th edition guidelines are the first to take HPV status into account.

Key results

  • OS was 100% (median 54 mo follow-up); estimated 3-y DFS was 87%.
  • Under 7th edition guidelines with pathologic data, 5% of patients were stage I, 11% were stage II, 26% were stage III, 57% were stage IVa, and 1% were stage IVb.
  • Under 8th edition guidelines, 94% of patients were stage I and 6% were stage II.
  • Under 7th edition guidelines, 25% of patients were upstaged and 14% were downstaged on final pathology after surgery.
  • Under 8th edition guidelines, 6% of patients were upstaged (P<.001 vs 7th edition) and 6% were downstaged (P=.0101 vs 7th edition) on final pathology.

Study design

  • 110 patients with HPV-positive OPC treated with TORS were analyzed for survival outcomes and staging by 7th and 8th edition AJCC guidelines.
  • Funding: None disclosed.

Limitations

  • Retrospective study.